In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection
Molecular Therapy Nucleic Acids · 2025-03 · 36 (1) · 102467
DOI: 10.1016/j.omtn.2025.102467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Nucleic Acids, 2025-03. Verfasst von Yuta Suzuki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki 300-2635, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai, High Energy Accelerator Research Organization, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants repeatedly evade the immune system within short periods. Thus, next-generation therapeutics that are resistant to mutations and can be rapidly supplied to individuals in an emergency are required. Here, we designed an mRNA encoding an engineered angiotensin-converting enzyme 2 (ACE2) decoy, 3N39v4, composed of high-affinity ACE2 and a human immunoglobulin G Fc domain. The 3N39v4-encoded mRNA was encapsulated in lipid nanoparticles for efficient in vivo delivery. Systemic delivery of mRNA in mice resulted in a dose-dependent expression of 3N39v4 in plasma (20-261 μg/mL at 1-10 mg/kg) with sufficient tolerability. An improved pharmacokinetic profile of the produced protein was compared to injection of the 3N39v4 protein. In vivo-expressed 3N39v4 exhibited broad neutralization against nine SARS-CoV-2 variants and other sarbecoviruses, including the currently circulating Omicron subvariants JN.1 and BA.2.86. A single intravenous injection of 3N39v4-encoded mRNA resulted in a robust, dose-dependent improvement in the outcomes of mice infected with SARS-CoV-2. The mRNA treatment in monkeys produced 3N39v4 in sera, which inhibited the replication of the authentic viruses. The rapid development of mRNA drugs highlights the potential of mRNA-encoded ACE2 decoys in emergencies to combat diverse SARS-CoV-2 variants, including future variants.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki 300-2635, Japan.
- Kobe Research Laboratories, Eisai Co., Ltd., Kobe 650-0047, Japan.
- Department of Microbiology, Juntendo University School of Medicine, Tokyo 113-8421, Japan.
- Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
- Department of Infectious Diseases, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
- Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Förderung
- Eisai
- High Energy Accelerator Research Organization
- Japan Agency for Medical Research and Development
Zitieren
APA
Suzuki, Y., Miyazaki, T., Ida, Y., Suzuki, T., Itoh, Y., Nakao, S., Kondo, K., Kubara, K., Nishioka, K., Muto, H., Watari, R., Hirayama, T., Kakiuchi, D., Sato, S., Inoue, S., Uemoto, Y., Mukai, Y., Hoshino, A., Okamoto, T., & Matsui, J. (2025). In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection. Molecular Therapy Nucleic Acids, 36(1), 102467. https://doi.org/10.1016/j.omtn.2025.102467
Vancouver
Suzuki Y, Miyazaki T, Ida Y, Suzuki T, Itoh Y, Nakao S, et al. In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection. Molecular Therapy Nucleic Acids. 2025;36(1):102467. doi:10.1016/j.omtn.2025.102467
BibTeX
@article{Suzuki2025,
author = {Suzuki, Yuta and Miyazaki, Takayuki and Ida, Yoko and Suzuki, Tatsuya and Itoh, Yumi and Nakao, Shuto and Kondo, Keita and Kubara, Kenji and Nishioka, Keisuke and Muto, Hiroki and Watari, Ryuji and Hirayama, Toshifumi and Kakiuchi, Dai and Sato, Shinya and Inoue, Satoshi and Uemoto, Yoshifumi and Mukai, Yohei and Hoshino, Atsushi and Okamoto, Toru and Matsui, Junji},
title = {In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection},
journal = {Molecular Therapy Nucleic Acids},
year = {2025},
volume = {36},
number = {1},
pages = {102467},
doi = {10.1016/j.omtn.2025.102467}
}
EUVIMED